Table of Contents
Overview
New York, NY – March 31, 2026 – The Global Preeclampsia Diagnostics Market size is expected to be worth around US$ 5.8 Billion by 2034, from US$ 2.2 Billion in 2024, growing at a CAGR of 10.2% during the forecast period from 2025 to 2034. North America held a dominant market position, capturing more than a 38.6% share and holds US$ 0.8 Billion market value for the year.
The preeclampsia diagnostics market is witnessing growth, supported by rising maternal health awareness and increasing incidence of hypertensive disorders during pregnancy. Preeclampsia, characterized by elevated blood pressure and organ dysfunction after 20 weeks of gestation, requires timely detection to reduce maternal and neonatal complications. Consequently, demand for reliable diagnostic solutions, including biomarker-based blood tests, urine protein analysis, and Doppler ultrasound assessments, is expanding across hospitals and maternity centers.
Growth is further supported by advancements in predictive biomarkers such as placental growth factor and sFlt-1 ratio testing, which enable risk stratification and earlier clinical intervention. Adoption is also increasing in emerging economies due to improving prenatal screening programs, government initiatives, and expansion of diagnostic infrastructure. In addition, integration of point-of-care testing and automated laboratory platforms is improving turnaround time and clinical decision-making efficiency.
North America and Europe continue to represent mature markets, driven by established screening guidelines and higher healthcare spending. Meanwhile, Asia-Pacific is projected to record growth, attributed to rising birth rates, improving access to antenatal care, and increasing investments in maternal health services.
Key industry participants are focusing on product innovation, regulatory approvals, and collaborations to strengthen their market presence. Overall, the market outlook remains cautiously optimistic, with continued emphasis on early detection and improved pregnancy outcomes.
Key Takeaways
- In 2024, the global preeclampsia diagnostics market generated revenue of US$ 2.2 billion and is
projected to reach US$ 5.8 billion by 2034, registering a CAGR of 10.2% during the forecast period. - Based on product type, the market is categorized into consumables and instruments. The consumables segment dominated in 2024, accounting for a 57.6% market share.
- By test type, the market is segmented into urine analysis, blood tests, and others. Blood tests represented the leading segment, capturing 48.3% of the total market share.
- In terms of end users, the market is divided into hospitals, diagnostic centers, specialty clinics, and others. Hospitals emerged as the dominant segment, holding the largest revenue share of 52.9%.
- Regionally, North America led the global preeclampsia diagnostics market, securing a 38.6% share in 2024.
Regional Analysis
North America accounted for the largest revenue share of 38.6% in 2024, supported by advancements in early detection technologies, increasing awareness, and a rising prevalence of high-risk pregnancies. Early diagnosis remains critical for effective maternal and fetal health management, driving adoption of advanced diagnostic tools.
Market growth has also been influenced by the introduction of predictive blood tests capable of identifying preeclampsia risk within a short timeframe, improving clinical decision-making and enabling timely interventions. In addition, growing demand for non-invasive and accurate diagnostic solutions, along with continued investments in maternal healthcare, is supporting regional expansion.
Emerging Trends
- Biomarker-Based Blood Tests: Biomarker-based blood tests detect preeclampsia early by measuring placental growth factor and soluble fms-like tyrosine kinase-1 levels. These FDA-approved assays predict severe risk within two weeks, improving monitoring, enabling earlier interventions, and enhancing maternal-fetal outcomes.
- First-Trimester Risk Assessment: First-trimester risk assessment evaluates preeclampsia between 11 and 14 weeks using biomarkers including placental growth factor and pregnancy-associated plasma protein-A, combined with blood pressure and uterine artery Doppler, enabling earlier preventive care.
- Wearable Monitoring Devices: Wearable monitoring devices continuously track maternal blood pressure and detect early hypertension signs. Smart bracelets transmit readings to healthcare providers, enabling rapid response, supporting remote care access, and improving monitoring in underserved regions.
- Machine Learning for Risk Prediction: Machine learning models analyze medical history, laboratory results, and blood pressure trends to predict preeclampsia risk. These algorithms generate personalized scores, improving prediction accuracy, supporting preventive planning, and enabling targeted management.
Use Cases
- Routine Prenatal Checkups: Routine prenatal checkups include blood pressure measurement and urine protein testing to identify preeclampsia early. Timely detection enables medication, monitoring, and lifestyle adjustments, reducing complications such as organ damage, premature birth, and adverse maternal outcomes.
- High-Risk Pregnancy Management: High-risk pregnancy management involves screening women with obesity, diabetes, chronic hypertension, or previous preeclampsia. Biomarker testing identifies risk levels, enabling preventive strategies, closer monitoring, low-dose aspirin therapy, and reduced likelihood of severe complications.
- Hospital-Based Interventions: Hospital-based interventions rely on advanced diagnostics, including sFlt-1 and placental growth factor ratio testing. Results assess severity, guide treatment decisions, determine delivery timing, and reduce risks of seizures, organ damage, and fetal distress.
- Remote Monitoring in Rural Areas: Remote monitoring in rural areas uses wearable devices and telemedicine platforms to track blood pressure continuously. Healthcare providers receive alerts for abnormal readings, enabling early intervention, reducing travel needs, and improving maternal outcomes.
Frequently Asked Questions on Preeclampsia Diagnostics
- What tests are commonly used for diagnosing preeclampsia?
Common tests include urine protein analysis, serum creatinine, liver enzyme evaluation, platelet count, and angiogenic biomarker measurements such as sFlt-1/PlGF ratio. Ultrasound and Doppler studies support assessment by monitoring fetal growth, placental function, and uteroplacental blood flow abnormalities. - Why is early detection of preeclampsia important?
Early diagnosis helps clinicians stratify risk, initiate antihypertensive therapy, administer corticosteroids for fetal lung maturity, and plan delivery timing. Accurate diagnostics reduce severe complications, including eclampsia, HELLP syndrome, organ failure, and long-term cardiovascular risks for mothers. - What is the role of biomarkers in preeclampsia diagnostics?
Biomarkers such as placental growth factor and soluble fms-like tyrosine kinase-1 improve predictive accuracy by identifying placental dysfunction before clinical symptoms appear. These assays support triage decisions, reduce unnecessary hospitalizations, and optimize resource utilization in high-risk pregnancies. - How are point-of-care diagnostics impacting preeclampsia detection?
Point-of-care diagnostic devices enable rapid assessment of proteinuria and angiogenic markers in outpatient or emergency settings. Portable platforms shorten turnaround times, facilitate earlier referrals, and enhance monitoring in low-resource regions where laboratory infrastructure remains limited. - What factors are driving the growth of the preeclampsia diagnostics market?
The preeclampsia diagnostics market is driven by rising maternal age, increasing hypertension prevalence, improved prenatal screening guidelines, and expanding awareness. Technological advancements in biomarker testing, reimbursement support, and demand for early risk stratification further stimulate adoption across hospitals and clinics. - How is the preeclampsia diagnostics market segmented?
Market segmentation typically includes test type, technology, end user, and geography. Test categories cover proteinuria assays and angiogenic biomarkers, while technologies include immunoassays and molecular platforms. Hospitals, diagnostic laboratories, and maternity clinics represent major end users globally. - Which regions dominate the preeclampsia diagnostics market?
North America and Europe hold significant shares due to advanced prenatal care and biomarker adoption, whereas Asia-Pacific exhibits fastest growth. Expanding healthcare infrastructure, large birth cohorts, and government maternal health initiatives are increasing demand for cost-effective diagnostic solutions.
Conclusion
The preeclampsia diagnostics market is expanding steadily, supported by rising maternal health awareness, increasing hypertensive pregnancy cases, and demand for early detection solutions. Advancements in biomarker testing, first-trimester screening, wearable monitoring, and machine learning are improving predictive accuracy and clinical decision-making. Hospitals remain primary end users, while blood-based diagnostics dominate due to reliability and adoption.
North America leads with established screening frameworks, whereas Asia-Pacific demonstrates strong growth potential driven by expanding antenatal care access. Continued innovation, supportive healthcare initiatives, and integration of point-of-care technologies are expected to strengthen early diagnosis capabilities and improve maternal and neonatal outcomes globally.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
